



Certificate of analysis

SFC868-03-08

Operator: Jane Vowles

Date: 17/02/2016

Supervisor: Sally Cowley

Date: 08/05/2017

Signature: *SACowley*


Source of fibroblasts and reprogramming information

- SF868 from Oxford University Hospitals
21/02/2011
- Reprogrammed at UOXF-S
- Reprogrammed on 06/08/2015 at passage 4,
CB
- Cytotune v2 WP3 SOP10


Viability post-thaw and Morphology according to SOP19 passage 11

- Cell count immediately post-thaw 4.4×10^6
- Viability immediately post-thaw 91%
- Photo at 24h and 3 day post-thaw (scale bar = $100\mu\text{m}$):


24h post-thaw 80% plated



Day 3 post-thaw 20% plated



Sendai clearance: according to WP3 SOP15 undetectable at passage 11



SFC868-03-05

SFC868-03-08

+ control

- control

No Reverse Transcriptase

Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 38bp

Mycoplasma Test:

According to MycoAlert Lonza LT07-318

undetectable at passage **11**

Sample	Clone	Passage number	Initial	Reading 1	Reading 2	Ratio/Status
+ve control				2.99	167.9	56.15
-ve control				3.361	0.432	0.13
10	SFC868-03-08	p1+10	JV	2.85	1.92	0.67

Results mean


Ratio **0 - 0.999** negative for mycoplasma

Ratio **1 – 1.3** Borderline Result (retest required)


Ratio above **1.3** positive for mycoplasma

Flow cytometric analysis according to WP3 SOP 20 and 21 passage 11

Tra-1-60:



NANOG:



SNP analysis

according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage 11
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected For details and raw data see StemDB NB first SNP run 01.2016 gave high allele intensity, but re-run 07.2016 is OK, checked at UOXF by Karyostudio